Drug Search Results
More Filters [+]

Vabicaserin

Alternative Names: vabicaserin, sca-136, sca136, sca 136
Latest Update: 2024-05-06
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: 5-HT2C Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Vabicaserin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Schizophrenia

Phase 1: Healthy Volunteers|Schizophrenia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

3153B3-1128

P1

Completed

Healthy Volunteers

2009-09-01

3153B1-2208

P2

Withdrawn

Schizophrenia

2009-07-01

3153A1-2203

P2

Completed

Schizophrenia

2008-06-01

3153A1-103

P1

Completed

Schizophrenia

2006-08-01

Recent News Events